Vivos Therapeutics, Inc. NASDAQ: VVOS
Vivos Therapeutics, Inc.
Annual Shareholder Meeting
August 25, 2022
Download Vivos Therapeutics, Inc.
2021 Annual Report
An Important Breakthrough in the Treatment for Mild-to-Moderate Obstructive Sleep Apnea
Vivos offers a multidisciplinary treatment protocol that uses nonsurgical, noninvasive, and cost-effective oral appliance technology prescribed by trained dentists and medical professionals to treat dentofacial abnormalities and/or mild-to-moderate OSA. This revolutionary treatment is called The Vivos Method.
Latest Stock Information
Listen to Kirk Huntsman and Brad Amman at the
34th Annual Roth Conference
Download the Vivos Investor Presentation
Fast Company Selects Vivos Therapeutics for 2022
“World’s Most Innovative Companies” List
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Our leadership team is devoted to a singular mission: to rid the world of sleep apnea.
Vivos Therapeutics Announces Multiple Regulatory Clearances in Australia for Its Entire Line of Oral Appliances
Australia clears Vivos technology to treat obstructive sleep apnea for all ages and regardless of severity in broad regulatory win. LITTLETON...
Vivos Therapeutics Announces Exclusive Distribution Agreement with GM Instruments, Ltd. for the U.S. and Canada
Effectively Immediately, Vivos to be Exclusive Distributor for Novel Diagnostic Equipment to Evaluate Nasal Breathing and Function in Dental...
Vivos Therapeutics’ SLEEP 2022 Annual Meeting Presentation Highlights Retrospective Study Demonstrating Significant Improvement in Sleep Apnea
Study Recently Presented at the SLEEP 2022 Annual Meeting LITTLETON Colorado, June, 14, 2022 GLOBE NEWSWIRE) -- Vivos Therapeutics,...